Analytica names new director


By Dylan Bushell-Embling
Monday, 13 January, 2014

Analytica (ASX:ALT) has appointed 30-year biotechnology veteran Carl Stubbings to the role of non-executive director, effective today.

Stubbings is currently chief business officer of Benitec Biopharma (ASX:BLT), where he focuses on commercialisation efforts including licensing and partnership agreements. He is also a non-executive director for cancer diagnostics company Sienna Diagnostics.

Before joining these companies, Stubbings held roles including VP of sales and marketing for Focus Diagnostics - a subsidiary of US pathology provider Quest Diagnostics - and a founder and senior VP of the US division of Brisbane-based virus test developer Panbio (now part of Alere).

“Carl’s appointment strengthens our board’s marketing experience, particularly in the USA, positioning Analytica ideally as we move toward the launch of PeriCoach in 2014 in the largest healthcare market in the world,” Analytica chairman Dr Michael Monsour commented.

PeriCoach is Analytica’s medical device for strengthening the pelvic floor muscles in women with urinary incontinence.

The device is designed to transmit data via Bluetooth to users’ smartphones, tablets or laptops, to allow them to monitor progress and share the results with medical professionals.

Related News

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Elevated blood protein levels predict mortality

Proteins that play key roles in the development of diseases such as cancer and inflammation may...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd